You are here:

etravirine (Intelence)

Advice

Following a resubmission

etravirine (Intelence), in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is accepted for use within NHS Scotland for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatmentexperienced adult patients.

In HIV-1 infected adults, with resistance to currently available non-nucleoside reverse transcriptase inhibitors (NNRTIs) and at least three primary protease inhibitor (PI) mutations, who were receiving an optimised background regimen that included boosted darunavir plus nucleoside reverse transcriptase inhibitors (NRTIs) and optional enfuvirtide, etravirine achieved significant improvements in virological, immunological and clinical outcomes when compared with placebo.

Drug Details

Drug Name: etravirine (Intelence)
SMC Drug ID: 530/09
Manufacturer: Tibotec (Janssen-Cilag Ltd)
Indication: HIV-1
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 10 August 2009

Archived Advice

Full submission 9 February 2009

Back